Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://onlinelibrary.wiley.com/doi" to "https://doi.org") |
m |
||
(One intermediate revision by one other user not shown) | |||
Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Acute lymphocytic leukemia]]=== | ===[[Acute lymphocytic leukemia]]=== | ||
− | # '''SWOG S0910:''' Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https://pubmed.ncbi.nlm.nih.gov/24579885 PubMed] [https:// | + | # '''SWOG S0910:''' Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https://doi.org/10.1111/bjh.12778 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209396/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24579885/ PubMed] [https://clinicaltrials.gov/study/NCT00945815 NCT00945815] |
==Also known as== | ==Also known as== |
Latest revision as of 23:13, 6 July 2024
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- SWOG S0910: Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. link to original article link to PMC article PubMed NCT00945815
Also known as
- Code name: AMG 412, hLL2
- Brand name: LymphoCide